Losartan Potassium
Product Images NDC 76519-1033

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 76519-1033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H.j. Harkins Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (76519 1033 Ppac Label)

LOSARTAN POTASSIUM 100 mg tablet packaging label showing the proprietary name, strength, tablet form, and manufacturer listed as H.J. Harkins Company, Inc. The label includes sections for NDC number, lot number, expiration date, and quantity, along with a caution statement about prescription use and safe storage instructions. The label references a comparison drug Cozaar and includes a printed instruction: Use As Directed by Physician.*

FDA Label Image

76519 1148 Ppac Label

LOSARTAN POTASSIUM 25mg tablet packaging label showing drug name, dosage strength, and comparation to Cozaar. The label includes expiration date, lot number, manufacturer (Camber Pharma), and account number. It contains multiple smaller label sections repeating the drug information including quantity and manufacturer NDC. The label advises use as directed by physician and includes a federal caution about dispensing.*

FDA Label Image

Figure1 (Figure1)

A line graph comparing the percentage of patients with primary endpoints over 60 study months for Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure2 (Figure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months between atenolol and losartan potassium. The graph shows data points for each treatment and includes an annotation about a 25% adjusted risk reduction with a p-value of 0.001.*

FDA Label Image

Figure3 (Figure3)

A forest plot figure presenting primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. The chart includes primary composite events and stroke (fatal/non-fatal) outcomes with event rates and hazard ratios (95% CI) across subgroups like age, gender, race, ISH status, diabetes, and history of cardiovascular disease, with symbols proportional to sample size.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing the percentage of patients with events over 48 months for Losartan potassium versus placebo. The graph shows two lines indicating a risk reduction of 16.1% with a p-value of 0.022, with time in months on the x-axis and percentage of patients with events on the y-axis.*

FDA Label Image

Image (Image)

Chemical structure of Losartan Potassium showing its molecular configuration including the chlorinated pyrimidine ring, hydroxyl group, butyl side chain, and associated potassium salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.